Middleton & Co. Inc. MA Purchases 525 Shares of Zoetis Inc. $ZTS

Middleton & Co. Inc. MA raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.0% in the second quarter, Holdings Channel reports. The firm owned 13,498 shares of the company’s stock after acquiring an additional 525 shares during the quarter. Middleton & Co. Inc. MA’s holdings in Zoetis were worth $2,105,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ZTS. Nova Wealth Management Inc. purchased a new stake in Zoetis during the 1st quarter valued at $25,000. 1248 Management LLC purchased a new position in shares of Zoetis in the first quarter worth $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the first quarter valued at $29,000. Cornerstone Planning Group LLC lifted its holdings in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC boosted its position in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.6%

Shares of ZTS stock opened at $119.81 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a fifty day simple moving average of $144.93 and a two-hundred day simple moving average of $152.78. The firm has a market capitalization of $53.10 billion, a PE ratio of 20.62, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 52-week low of $119.06 and a 52-week high of $181.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Stifel Nicolaus set a $140.00 target price on shares of Zoetis in a research note on Tuesday. Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. UBS Group lowered their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, Piper Sandler upped their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Moderate Buy” and a consensus target price of $191.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.